NCT03445650View on ClinicalTrials.gov

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 18, 2018

Primary Completion Date

January 18, 2020

Study Completion Date

January 18, 2020

Conditions
Sjogren-Larsson Syndrome
Interventions
DRUG

ADX-102 1% Topical Dermal Cream (reproxalap)

ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.

DRUG

Vehicle of ADX-102 Topical Dermal Cream

Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.

Trial Locations (2)

68198

University of Nebraska Medical Center, Omaha

06519

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY